These results are consistent with the previous evidence on the (T cell dependent) immunosupresive role of IDO1 in melanoma and its effect on survival, which resulted in suggestion of IDO1 inhibitors as a promising cancer treatment target47–49. The gene discussed is IDO1; the disease is cancer.